The post Dogecoin Triangle Support Test Maps Out Recovery Roadmap And When To Sell appeared on BitcoinEthereumNews.com. Dogecoin (DOGE) is testing the lower boundaryThe post Dogecoin Triangle Support Test Maps Out Recovery Roadmap And When To Sell appeared on BitcoinEthereumNews.com. Dogecoin (DOGE) is testing the lower boundary

Dogecoin Triangle Support Test Maps Out Recovery Roadmap And When To Sell

For feedback or concerns regarding this content, please contact us at [email protected]

Dogecoin (DOGE) is testing the lower boundary of a long-term triangle pattern, a move that could determine its next major price direction. A new technical analysis highlights a roadmap with key recovery levels and outlines a potential timeframe when selling and profit-taking may become favorable.

Dogecoin Triangle Pattern Signals Recovery Path

In a recent X post, crypto analyst Jonathan Carter presented a new analysis of Dogecoin’s price action, predicting that a potential recovery may be imminent. Carter explained that Dogecoin is currently testing a critical support area around $0.135 within a long-standing descending triangle chart structure. The setup is unfolding over the 3-day timeframe, with price action remaining above the pattern’s lower boundary. This zone has become a key battlefield between buyers and sellers. 

Carter highlights that the ongoing support area offers a favorable risk-reward profile for market participants. Buyers stepping in at this level are attempting to prevent a breakdown that could invalidate the broader recovery outlook. This means holding above this support zone could keep Dogecoin’s bullish scenario intact.

The descending triangle visible on the analyst’s shared chart shows a series of lower highs pressing against the stable support zone at $0.135. This compression often precedes a decisive move once the price reacts strongly at the base. Dogecoin’s current structure also suggests the market is steadily approaching that inflection point.

The volume data at the bottom of the chart has yet to show strong expansion near the support area. This indicates that Dogecoin’s trading activity has been relatively muted, suggesting that the market may be waiting for confirmation before committing to a significant upward move. 

If Dogecoin successfully rebounds from the $0.135 support zone, Carter’s chart maps out several upside levels to watch. Initial recovery targets are seen around $0.155 and $0.190, where previous price reactions occurred. Clearing these levels would signal growing momentum and a possible end to DOGE’s downtrend.

Further upside extensions projected on the chart include $0.250 and $0.310, which align with previous consolidation areas. A stronger continuation could open the path toward $0.370 and ultimately the resistance zone near $0.470.

Resistance Zone Reveals When To Sell DOGE 

Carter’s Dogecoin chart clearly shows the $0.47 resistance zone, where sellers are expected to become active again. A rally into the zone would likely face increased selling pressure based on historical price behaviour. As a result, the resistance area serves as a strategic level for profit-taking rather than for new entries in Dogecoin. 

Overall, Carter’s analysis suggests that Dogecoin’s price is sitting at a pivotal technical level that could shape its next major move. The meme coin’s price is currently down, having crashed by over 22% year-to-date, according to CoinMarketCap. Despite this slip, Carter remains optimistic about DOGE’s recovery path. The recovery timeline highlighted in the analysis suggests that by 2026, the meme coin may have emerged from its downturn. 

Featured image from Unsplash, chart from TradingView

Source: https://www.newsbtc.com/altcoin/dogecoin-triangle-support-test-maps-out-recovery-roadmap-and-when-to-sell/

Market Opportunity
DOGE Logo
DOGE Price(DOGE)
$0.09031
$0.09031$0.09031
+0.05%
USD
DOGE (DOGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09